Literature DB >> 3719103

Fragment D-dimer levels: an objective marker of vaso-occlusive crisis and other complications of sickle cell disease.

D V Devine, T R Kinney, P F Thomas, W F Rosse, C S Greenberg.   

Abstract

Although abnormalities in coagulation tests have been reported during vaso-occlusive crises in patients with sickle cell disease, objective, readily performed laboratory tests that document the occurrence of this complication have not been available. We examined the relationship between fibrin D-dimer levels and the occurrence of complications in patients with sickle cell disease, using a commercially available latex bead agglutination assay. The patients were either asymptomatic, hospitalized for vaso-occlusive crisis, or had other complications of sickle cell disease including leg ulcers, chronic cholecystitis, aseptic necrosis, joint pain and infection. Fifty-seven percent of 187 samples on 96 patients had elevated levels of fibrin D-dimer. Ninety percent of 75 samples from asymptomatic patients were negative for fibrin D-dimer (less than 1 microgram/ml) but 97% of 29 samples from patients with vaso-occlusive crisis and 85% of 83 samples from patients with other complications of sickle cell disease were positive. In serial studies, worsening or amelioration in clinical complications were reflected in increasing or decreasing levels of fibrin D-dimer, respectively. The molecular species of fibrin identified by the latex agglutination test was shown to be fragment D-dimer by successive immunoprecipitation and protein blot analysis. We conclude that the complications of sickle cell disease, including vaso-occlusive crisis, result in the production of fibrin D-dimer, and its detection may be used as a marker for the presence of the complication.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3719103

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Factors associated with positive D-dimer results in patients evaluated for pulmonary embolism.

Authors:  Christopher Kabrhel; D Mark Courtney; Carlos A Camargo; Michael C Plewa; Kristen E Nordenholz; Christopher L Moore; Peter B Richman; Howard A Smithline; Daren M Beam; Jeffrey A Kline
Journal:  Acad Emerg Med       Date:  2010-06       Impact factor: 3.451

Review 2.  Red blood cells in thrombosis.

Authors:  James R Byrnes; Alisa S Wolberg
Journal:  Blood       Date:  2017-08-15       Impact factor: 22.113

3.  Serum D-dimer concentrations are increased after pediatric traumatic brain injury.

Authors:  Rachel P Berger; Janet Fromkin; Pam Rubin; John Snyder; Rudolph Richichi; Patrick Kochanek
Journal:  J Pediatr       Date:  2014-11-20       Impact factor: 4.406

4.  Successful treatment of ileal pouch desmoids using multimodal chemotherapy with low-dose vinblastine and methotrexate in a patient with familial adenomatous polyposis.

Authors:  Yuji Toiyama; Naomi Konishi; Yasuhiro Inoue; Shigeyuki Yoshiyama; Toshimitsu Araki; Chikao Miki; Masato Kusunoki
Journal:  Clin J Gastroenterol       Date:  2009-01-24

5.  Raised D-dimer levels in acute sickle cell crisis and their correlation with chest X-ray abnormalities.

Authors:  Javeed Dar; Inam Mughal; Hilali Hassan; Taj E Al Mekki; Zivani Chapunduka; Imad S A Hassan
Journal:  Ger Med Sci       Date:  2010-10-08

6.  Tissue type plasminogen activator antigen and activity in sickle cell disease.

Authors:  R B Francis
Journal:  J Clin Pathol       Date:  1988-05       Impact factor: 3.411

7.  Calpain-1 regulates platelet function in a humanized mouse model of sickle cell disease.

Authors:  Jennifer O Nwankwo; Thomas Gremmel; Anja J Gerrits; Farha J Mithila; Rod R Warburton; Nicholas S Hill; Yunzhe Lu; Lauren J Richey; Joseph A Jakubowski; Andrew L Frelinger; Athar H Chishti
Journal:  Thromb Res       Date:  2017-10-26       Impact factor: 3.944

8.  Characterization of the hypercoagulable state in patients with sickle cell disease.

Authors:  Nirmish Shah; Courtney Thornburg; Marilyn J Telen; Thomas L Ortel
Journal:  Thromb Res       Date:  2012-09-07       Impact factor: 3.944

9.  Which adults with sickle cell disease need an evaluation for pulmonary embolism?

Authors:  Nadirah El-Amin; Steven D Lauzon; Paul J Nietert; Julie Kanter
Journal:  Br J Haematol       Date:  2021-09-01       Impact factor: 6.998

Review 10.  Biomarkers and recent advances in the management and therapy of sickle cell disease.

Authors:  Marilyn J Telen
Journal:  F1000Res       Date:  2015-10-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.